Ronald Asbury Andrews, CEO and President at OncoCyte Corp (OCX), bought 90,432 shares at $2.26 ($208K) on 2020-03-30, disclosed to the SEC on 2020-04-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.26 | 27,216 | $62K | 29.5% |
| 2 | $2.26 | 27,216 | $62K | 29.5% |
| 3 | $2.37 | 18,000 | $43K | 20.5% |
| 4 | $2.37 | 18,000 | $43K | 20.5% |
| Total | $2.30 avg | 90,432 | $208K | 100% |
| Filing → |
| OCX | BUY | 2021-03-22 | $53K | — | Filing → |
| OCX | BUY | 2020-08-04 | $54K | — | Filing → |
| OCX | BUY | 2020-04-01 | $42.7M | — | Filing → |